Skip to main content
. Author manuscript; available in PMC: 2006 Dec 12.
Published in final edited form as: Clin Cancer Res. 2005 Jun 15;11(12):4545–4552. doi: 10.1158/1078-0432.CCR-04-2235

Fig. 4.

Fig. 4

Antitumor reactivity of STEAP-292 peptide–induced CTL lines. Tumor lines were evaluated including COLO205 (●) and, as a negative control, J82 (○). In addition, T2 cells with no peptide (■)and with STEAP-292(□) were evaluated as negative and positive controls, respectively. Antitumor cytolytic activity was measured using a 4-hour 51Cr-release cytolysis assay at various effector/target ratios.